Eicosanoids pp 99-103 | Cite as

PGHS-2 Dependent Formation of 8-Epi PGF by Human Monocytes

  • Domenico Praticò
  • Garret A. Fitzgerald
Part of the NATO ASI Series book series (NSSA, volume 283)


Arachidonic acid is converted enzymatically into different prostaglandins (PG) by the activity of a key enzyme, PG-endoperoxide synthase (PGHS), which exhibits both bisoxygenase and peroxidase activity (1). Cell-specific isomerization or reduction of PGH2 by various synthases (isomerases) or reductases leads to the formation of different prostanoids (2). It has been demonstrated that mammalian cells contain two isoforms of PGHS referred to as PGHS-1 and PGHS-2, encoded by separated genes (3). PGHS-1 is constitutively expressed in most tissue including platelets, endothelial cells and monocytes. However, it is recognized that expresion of PGHS-1 may be regualted. For example, androgens upregulate PGHS-1 in seminiferous tubules (4), as do cytokines in bone marrow derived mast cells (5). PGHS-2 expression is readily induced by serum, growth factors, cytokines in wide variety of cell types (6,7). Conventionally, this has implied the predominant importance of this isoform in regulating the inflammatory response. Data consistent with this view of the roles of the two enzymes have been obtained from “knock out” mice (8–10). Thus, while the PGHS-1 knock out exhibits a normal phenotype (8), inflammatory responses were modified following disruption of the PGHS-2 gene (9).


Human Monocyte Bone Marrow Derive Mast Cell Fresh Peripheral Blood Mononuclear Cell Human Prostaglandin Prostanoid Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Smith W.L, Marnett LJ, De Witt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol. Ther. 49: 153–179, 1991.PubMedCrossRefGoogle Scholar
  2. De Witt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim. Biophys. Acta 1083: 121–134, 1991.CrossRefGoogle Scholar
  3. Smith WL. Prostanoid biosynthesis and mechanism of action. Am.J.Physiol. 263: F181–F191, 1992.PubMedGoogle Scholar
  4. Silvia WJ, Brockmann JA, Kaminski MA, DeWitt DL, Smith WL. Prostaglandin endoperoxide synthase in seminal vesicles. Mol. Androl. 6: 197–207, 1994.Google Scholar
  5. Murakami M, Matsumoto R, Austen FK, Arm JP. Prostaglandin endoperoxide synthase-1 and-2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow derived mast Cells. J.Biol.Chem. 269: 22269–22275, 1994.PubMedGoogle Scholar
  6. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S, Simmons D, Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipolysaccaride. J. Biol. Chem. 267: 25934–25938, 1992PubMedGoogle Scholar
  7. O’Sullivan MG, Huggins EM, McCall CE. Lipolysaccaride-induced expression of prostaglandin H synthase-2 in alveolar macrophages is inhibited by dexamethasone but not by aspirin. Biochem.Biophys. Res.Commun. 191: 1294–1300, 1993.PubMedCrossRefGoogle Scholar
  8. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O. Protasglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83: 483–492, 1995.PubMedCrossRefGoogle Scholar
  9. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473–482, 1995.PubMedCrossRefGoogle Scholar
  10. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandins F2-like compounds are produced in vivo in human by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 87: 9383–9387, 1990.PubMedCrossRefGoogle Scholar
  11. Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi Prostaglandin F . J.Biol. Chem. 270: 9800–9808, 1995.PubMedCrossRefGoogle Scholar
  12. Wang Z, Ciabattoni G, Creminon C, Lawson J, FitzGerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi Prostaglandin F excretion in man. J.Pharm. Exper. Therap. 275: 94–100, 1995.Google Scholar
  13. Takahashi K, Nammour TM, Fukunaga M, Ebert J, Morrow JD, Roberts LJ, Hoover RL, Badr KF. Glomerular action of a free radical-generated novel prostaglandin, 8-epi PGF in the rat. J. Clin. Invest. 90: 136–141, 1992.PubMedCrossRefGoogle Scholar
  14. Picot D, Loll PJ, Garavito MR. The X-ray crystal srtucture of the menbrane protein prostaglandin H2 synthase-1. Nature 367: 243–249, 1994.PubMedCrossRefGoogle Scholar
  15. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J.Biol.Chem. 269: 13207–13215, 1994.PubMedGoogle Scholar
  16. Mancini JA, O’Neill GP, Bayly C, Vickers PJ. Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulate 15-R-HETE synthesis. FEBS Lett. 342: 33–37, 1994.PubMedCrossRefGoogle Scholar
  17. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest. 21: suppl. 97–89, 1968.Google Scholar
  18. Habib A, Creminon C, Frobert Y, Grassi J, Pradelles P, Maclouf J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl terminal region of the cyclooxygenase-2. J. Biol.Chem. 268: 23448–23454, 1993.PubMedGoogle Scholar
  19. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, Penneton M, Prasit P, Rasori R, Riendeau D, Roy P, Tagari P, Vickers P, Wong E, Rodger IW. Pharmacology of a selective cyclooxygenase-2 inhibityor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J.Pharmacol. Exp. Therap. 274: 1531–1537, 1995.Google Scholar
  20. Banerjee M, Kang KH, Morrow JD, Roberts LJ, Newman JH. Effects of a novel prostaglandin, 8-epi PGF in rabbit lung in situ. Am. J. Physiol. 263: H660–H663. 1992.PubMedGoogle Scholar
  21. Funkunaga M, Makita N, Roberts LJ, Morrow LD, Takahashi K, Badr KF. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am.J.Physiol. 264: C1619–C1624,1993.Google Scholar
  22. Gerrity RG. The role of the monocytes in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am.J.Pathol. 103: 181–190, 1981.PubMedGoogle Scholar
  23. Gerrity RG. The role of the monocytes in atherogenesis. II. Migration of foam cells from atherosclerotic lesions. Am.J.Pathol. 103: 191–200, 1981.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Domenico Praticò
    • 1
  • Garret A. Fitzgerald
    • 1
  1. 1.The Center for Experimental TherapeuticsThe University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations